MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
Lexicon Pharmaceuticals EV - Enterprise Value 2011-2026 | LXRX
Annual EV - Enterprise Value Lexicon Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 635 M | 201 M | 583 M | 487 M | 533 M | -78.8 M | 604 M | 697 M | 1.48 B | 1.69 B | 1.22 B | 536 M | 1.01 B | 1.11 B | 454 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.69 B | -78.8 M | 744 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
1.22 B | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
82.4 M | $ 3.25 | 3.83 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
9.45 M | $ 0.79 | 0.03 % | $ 4.31 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
114 M | $ 4.12 | -1.9 % | $ 105 M | Schweiz |
 |
Arcturus Therapeutics Holdings
ARCT
|
43.4 M | $ 6.55 | -1.28 % | $ 179 M |  Israel |
 |
argenx SE
ARGX
|
-796 M | $ 709.08 | 0.82 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.43 | -4.99 % | $ 8.25 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
849 M | $ 229.99 | -0.45 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
370 M | $ 6.09 | 0.58 % | $ 496 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioCardia
BCDA
|
12.4 M | $ 1.29 | 1.24 % | $ 27.3 M | USA |
 |
Anika Therapeutics
ANIK
|
300 M | $ 14.55 | 1.32 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
10.8 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
86.9 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-15.2 M | $ 2.62 | -0.75 % | $ 16.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.51 | - | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-18.3 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
-4.91 B | $ 94.12 | 3.95 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
3.22 B | $ 8.27 | 2.54 % | $ 1.34 B | Britain |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.5 | -2.51 % | $ 7.62 B | Israel |